-- 根據FactSet調查的分析師報告，Astera Labs (ALAB) 的平均評級為“增持”，平均目標價為243.25美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）
Price: $204.83, Change: $-10.86, Percent Change: -5.04%
Related Articles
Treasury
US Treasury Closing Levels
3:00 Tuesday vs 3:00 Monday2yr 99-24 vs 99-20; 3.867% vs 3.934%5yr 99-13 vs 99-04; 4.001% vs 4.069%10yr 98-05 vs 97-23; 4.354% vs 4.413%30yr 97-00 vs 96-13+; 4.941% vs 4.980%2/10 48.437 bps vs 47.739 bps5/30 93.871 bps vs 90.966 bps
Research
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Marriott International Inc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target by $13 to $383, based on a 20x 2026 EV/EBITDA multiple (up from 19x), a premium to its 17x three-year average forward multiple. We raise our 2026 EPS estimate to $11.83 from $11.55 and 2027's to $12.98 from $12.69. In Q1 results, domestic RevPAR growth of 4% was driven by ADR and occupancy. Encouragingly, the performance broadened out from luxury segments, which had been the primary drivers of domestic RevPAR growth in 2025. Despite Middle East disruptions, MAR raised its 2026 RevPAR outlook to a range of 2%-3% (from 1.5%-2.5%), highlighting the World Cup event and market share gains in China. However, we maintain our Hold opinion. At current levels, shares trade at 12% premium to their three-year average, suggesting RevPAR momentum is already priced in. The World Cup tailwind, while supportive for 2026, creates a tougher comparison for 2027 RevPAR growth. We view guidance as appropriately conservative on potential macro disruptions but see limited upside to our revised estimates.
$MAR
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Eog Resources
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $153, raised $16, reflects a combination of relative valuation and DCF models. On a relative basis, we apply a 5.2x multiple of enterprise value to projected 2027 EBITDA, about in line with EOG's historical forward average, and yielding a value of $125 per share. Meanwhile, our DCF model, assuming medium-term free cash flow growth of 5.0%, terminal growth of 2.5%, discounted at a WACC of 7.1%, yields intrinsic value of $181 per share. We lift our 2026 EPS estimate by $6.25 to $15.75 and 2027's by $1.54 to $13.17. EOG's production profle is still skewed toward liquids (63% of expected production in 2026), but considerably less so following the closure of the Encino acquisition. EOG did experience some cost pressures in Q1, which we think are a function of digesting Encino (closed in Q3 2025), but we note the company's long track record of cost efficiency improvements and expect it to get back on track in the near future.
$EOG